CN103442733A - 皮肤病学病状的治疗 - Google Patents

皮肤病学病状的治疗 Download PDF

Info

Publication number
CN103442733A
CN103442733A CN2012800140133A CN201280014013A CN103442733A CN 103442733 A CN103442733 A CN 103442733A CN 2012800140133 A CN2012800140133 A CN 2012800140133A CN 201280014013 A CN201280014013 A CN 201280014013A CN 103442733 A CN103442733 A CN 103442733A
Authority
CN
China
Prior art keywords
human
subject
skin inflammation
mab
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800140133A
Other languages
English (en)
Chinese (zh)
Inventor
J·西马德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
XBIOTECH Inc
Original Assignee
XBIOTECH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XBIOTECH Inc filed Critical XBIOTECH Inc
Priority to CN201910233038.6A priority Critical patent/CN110201157A/zh
Publication of CN103442733A publication Critical patent/CN103442733A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2012800140133A 2011-04-01 2012-04-02 皮肤病学病状的治疗 Pending CN103442733A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910233038.6A CN110201157A (zh) 2011-04-01 2012-04-02 皮肤病学病状的治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470538P 2011-04-01 2011-04-01
US61/470,538 2011-04-01
PCT/US2012/031803 WO2012135812A2 (en) 2011-04-01 2012-04-02 Treatment for dermatological pathologies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910233038.6A Division CN110201157A (zh) 2011-04-01 2012-04-02 皮肤病学病状的治疗

Publications (1)

Publication Number Publication Date
CN103442733A true CN103442733A (zh) 2013-12-11

Family

ID=46927554

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2012800140133A Pending CN103442733A (zh) 2011-04-01 2012-04-02 皮肤病学病状的治疗
CN201910233038.6A Pending CN110201157A (zh) 2011-04-01 2012-04-02 皮肤病学病状的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910233038.6A Pending CN110201157A (zh) 2011-04-01 2012-04-02 皮肤病学病状的治疗

Country Status (11)

Country Link
US (2) US20120251548A1 (enExample)
EP (2) EP2694107B1 (enExample)
JP (2) JP6062918B2 (enExample)
KR (3) KR20190090046A (enExample)
CN (2) CN103442733A (enExample)
AU (2) AU2012236106B2 (enExample)
CA (1) CA2831126C (enExample)
DK (1) DK2694107T3 (enExample)
ES (1) ES2697056T3 (enExample)
PT (1) PT2694107T (enExample)
WO (1) WO2012135812A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011268229B2 (en) 2010-06-18 2015-04-16 Xbiotech Inc. Arthritis treatment
ES2622482T3 (es) 2010-08-23 2017-07-06 Xbiotech, Inc Tratamiento de enfermedades neoplásicas
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
KR20190090046A (ko) * 2011-04-01 2019-07-31 엑스바이오테크, 인크. 피부과학적 병리의 치료
CN108404127B (zh) 2011-09-23 2025-12-12 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
AU2013327498B2 (en) * 2012-10-04 2018-06-28 Janssen Biotech, Inc. Treatment of psychiatric conditions
SG11201907159SA (en) 2017-02-16 2019-09-27 Xbiotech Inc Treatment of hidradenitis suppurativa
CN115702023A (zh) * 2020-04-16 2023-02-14 詹森生物科技公司 化脓性汗腺炎的治疗
CA3095675A1 (en) * 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008082651A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
US20090298096A1 (en) * 2008-05-30 2009-12-03 Xbiotech, Inc. Interleukin-1 alpha ABS and methods of use
US20100221179A1 (en) * 2009-01-29 2010-09-02 Abbott Laboratories IL-1 Binding Proteins

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
CA2147151A1 (en) 1992-10-14 1994-04-28 Robert A. Snow Therapeutic and diagnostic imaging compositions and methods
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5945576A (en) * 1996-04-05 1999-08-31 Brigham & Women's Hospital, Inc. Mouse model of psoriasis
CA2426384A1 (en) 2000-10-19 2003-04-17 Kyowa Hakko Kogyo Co., Ltd. Antibody inhibiting vplf activity
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RS54163B1 (sr) 2006-05-30 2015-12-31 Genentech Inc. Anti-cd22 antitela, njihovi imunokonjugati i njihova upotreba
WO2010030979A2 (en) * 2008-09-12 2010-03-18 Xbiotech, Inc. Targeting pathogenic monocytes
JP5866130B2 (ja) * 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
KR20190090046A (ko) * 2011-04-01 2019-07-31 엑스바이오테크, 인크. 피부과학적 병리의 치료
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008082651A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
US20090298096A1 (en) * 2008-05-30 2009-12-03 Xbiotech, Inc. Interleukin-1 alpha ABS and methods of use
US20100221179A1 (en) * 2009-01-29 2010-09-02 Abbott Laboratories IL-1 Binding Proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H MIZUTANI ET AL.: "Endogenous neutralizing anti-IL-1α autoantibodies in inflammatory skin diseases: possible natural inhibitor for over expressed epidermal IL-1", 《JOURNAL OF DERMATOLOGICAL SCIENCE》 *

Also Published As

Publication number Publication date
CN110201157A (zh) 2019-09-06
EP2694107B1 (en) 2018-08-22
EP2694107A4 (en) 2014-10-01
PT2694107T (pt) 2018-11-27
KR102004554B1 (ko) 2019-10-01
JP6453278B2 (ja) 2019-01-16
KR20190090046A (ko) 2019-07-31
WO2012135812A3 (en) 2013-01-31
ES2697056T3 (es) 2019-01-21
AU2017201201B2 (en) 2018-12-13
US20160368982A1 (en) 2016-12-22
CA2831126C (en) 2019-11-12
US9902769B2 (en) 2018-02-27
JP6062918B2 (ja) 2017-01-18
KR102326482B1 (ko) 2021-11-17
EP2694107A2 (en) 2014-02-12
AU2012236106A1 (en) 2013-09-26
US20120251548A1 (en) 2012-10-04
DK2694107T3 (en) 2018-12-10
AU2017201201A1 (en) 2017-04-06
CA2831126A1 (en) 2012-10-04
AU2012236106B2 (en) 2016-12-08
JP2014509662A (ja) 2014-04-21
KR20140033036A (ko) 2014-03-17
KR20200145844A (ko) 2020-12-30
JP2017014228A (ja) 2017-01-19
EP3417879A1 (en) 2018-12-26
WO2012135812A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
US11191831B2 (en) Treatment of psychiatric conditions
JP6453278B2 (ja) 皮膚科的病理の治療
JP2022177132A (ja) 精神障害の治療
EP2608808A2 (en) Treatment for neoplastic diseases
AU2015201228B2 (en) Treatment for neoplastic diseases
HK40013773A (zh) 皮肤病学病状的治疗
HK1187260A (en) Treatment for dermatological pathologies
AU2015271978A1 (en) Treatment for neoplastic diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1187260

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20131211

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1187260

Country of ref document: HK